IGF gene-network identifies specific interactions underlying extreme SBP in developing children

NZSA Conference
University of Canterbury
November 2015

P.G. Parmar,
C.E. Pennell, L.J. Palmer, L. Briollais

Department of Biostatistics and Epidemiology
School of Public Health and Psychosocial Studies
Faculty of Health and Environmental Sciences
**AIM**

Investigate if modelling the insulin-like growth factor (IGF)-Axis as a gene-network can identify gene-interactions predictive of the early onset of elevated systolic blood pressure (SBP) in developing children.
RATIONALE

- Elevated BP is a symptom and a disease

- Consistent, persistent elevated BP (140mmHg SBP/90mmHg DBP) = Clinical Hypertension

- Established cardiovascular (CVD) risk-factor

- Is the leading cause of adult death and disability in the world through its predisposition to CVD events e.g. MI, stroke, obesity, type-II diabetes, metabolic syndrome
NEARLY 1 IN 3
PEOPLE HAS HIGH BLOOD PRESSURE.

Source: National Heart, Lung, and Blood Institute
HYPERTENSION

1.5 BILLION

by 2025

WORLDWIDE WILL HAVE HYPERTENSION
(ALSO KNOWN AS HIGH BLOOD PRESSURE)

77% of people who have their first STROKE

69% of people who have their first HEART ATTACK
Currently, it accounts for 7.5 million deaths per year.
Cardiovascular disease

Non-modifiable risk factors:
- Age
- Gender
- Genetic factors
- Race & ethnicity

Modifiable risk factors:
- High BP
- Smoking
- Diabetes mellitus
- Physical inactivity
- Obesity
- High blood cholesterol
High BP

Cardiovascular disease

Genetic Factors
- Race & ethnicity
- Gender

Non-modifiable risk factors
- Age
- Smoking
- Diabetes mellitus
- Physical inactivity
- Obesity
- High blood cholesterol

Modifiable risk factors
Why are we looking here?

Rather than here?
Heritable genetic, epigenetic and environmental factors can affect risk of ill-health in next generation.

Human reproductive cycle

Mother & Infant: effective point to intervene - biomarkers of risk

Child/adolescent: effective point to intervene

High risk trajectory

Low risk trajectory

Affected adult: interventions have limited effect

Adult: Screening may be too late to reduce risk

Plasticity

Detrimental effects of lifestyle challenges/increasing mismatch
BP DATA

- Raine (Western Australian Longitudinal Pregnancy and Birth Cohort)

- Data from 2,279 individuals who had at least one SBP measure recorded at 5, 8, 10, 12, 14 and 17 years of age

- The most being recorded at age five (1,947 individuals) and the least at the 17 year follow-up (1,249 individuals)
GENETIC DATA: IGF-Axis
## IGF-Axis

<table>
<thead>
<tr>
<th>Gene</th>
<th>Number of SNPs</th>
<th>Percentage of SNPs</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGF-1</td>
<td>15</td>
<td>9</td>
</tr>
<tr>
<td>IGF-1R</td>
<td>82</td>
<td>50</td>
</tr>
<tr>
<td>IGF-2</td>
<td>8</td>
<td>5</td>
</tr>
<tr>
<td>IGF-2R</td>
<td>38</td>
<td>23</td>
</tr>
<tr>
<td>IGFBP1</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>IGFBP2</td>
<td>4</td>
<td>2</td>
</tr>
<tr>
<td>IGFBP3</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>IGFBP4</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>IGFBP5</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>165</strong></td>
<td><strong>100</strong></td>
</tr>
</tbody>
</table>
THE MODEL

- Following Tsonaka *et al*, we used a two-stage mixed effects model to estimate a gene interaction network involving the nine genes of the IGF axis and model their association with the longitudinal SBP outcome.

- Stage 1 generates gene-based random effects summarising the SNP effects within each gene.

- Stage 2 uses the gene-specific random effects from stage 1 to model the gene-gene interactions against SBP.
STAGE 1: Genetic Model

- Here we model the probability of carrying a particular SNP allele (the rare allele) as a function of fixed and random effects that represent genetic variations of the SNP genotypes at S loci studied.

- A logistic model is used to specify the probability to carry at least one rare allele (dominant model) or two rare alleles (recessive model) as a Bernoulli trial.

- This model will return the empirical Bayes (EB) estimates of the random effects.
STAGE 1: Genetic Model

Let $\pi_{ij}$ be the probability for an individual $i$ ($i = 1, \ldots, n$) to carry a variant in the SNP $j = (1, \ldots, 165)$ across the particular gene it belongs to, given we have 9 genes $g = (1, \ldots, 9)$. The gene-based lme can be written as:

$$\log \frac{\pi_{ij}}{1-\pi_{ij}} = X'_{ij} \beta' + b_i + b_{ij} + b_{ijg}$$

- $\beta'$ is a vector of regression coefficients on specific covariates $X_{ij}$'s that could account for specific SNP characteristics, if any is included.

- $b_{i0} \sim N(0, \sigma^2)$ is a random intercept effect for each individual $i$.

- $b_{ij} \sim N(0, \sigma_g^2)$ is a random effect for each SNP $j$ within individual $i$. It is assumed independent for each individual $i$ and independent of $b_{i0}$, but the $b_{ij}$’s are correlated across genes.

- $b_{ijg} \sim N(0, \sigma_g^2)$ is a random effect for each gene $g$ and SNP $j$ within individual $i$. It is assumed independent for each individual $i$ and independent of $b_i$ and $b_{ij}$.

- For each individual and each gene, an empirical bayes estimate can be obtained from the gene-based lme by adding the three random effects:

$$\widehat{eb}_{ig} = \widehat{b}_i + \widehat{b}_{ij} + \widehat{b}_{ijg}$$
STAGE 2: Longitudinal Model

- Here gene-specific estimates are tested using the EB estimates ($\hat{eb}_{ig}$) from the first stage as covariates in the mixed-effects model for longitudinal SBP.

- To model the longitudinal outcome, a linear mixed-effects model with random intercepts and random slopes was used.

- A model fitting procedure was implemented to identify the optimal set of variables that should be included in this longitudinal gene-network model.

  - Age, Sex and BMI
STAGE 2: Longitudinal Model

\[ SBP_{it} \sim X'_{it}\beta + \sum_{g=1}^{G} \sum_{g' > g} \{eb_{ig}^*\} \{eb_{ig'}^*\} \gamma + \sum_{g=1}^{G} \sum_{g' > g} \{eb_{ig}^*\} \{eb_{ig'}^*\} (BMI_{it} + (Age_{it} \ast Sex_i)) \eta + u_i + \epsilon_{it} \]

- \( t = 1, \ldots, 5 \) represents the number of follow-up visits at approximately (1) 5 years, (2) 8 years, (3) 10 years, (4) 14 years and (5) 17 years.
- \( X_{it} \) = Design matrix for the fixed effect covariates which include; BMI, sex and age.
- \( Age_{it} = 5\text{-}14 \text{ years vs. 15+ years. In brief, these timeframes were chosen to reflect dramatic changes in developmental growth. Further justification surrounding these ‘epochs’ can be found in chapters six and seven.} \)
- \( Sex_i = \text{Males or Females} \)
- \( BMI_{i} = \text{per unit (kg/m}^2\text{) increase in year of age} \)
- \( \beta = \text{Vector of regression coefficients on the fixed effects variables BMI, sex and age} \)
- \( eb_{ig}^* = \text{gene-specific empirical Bayes random effects estimated from stage 1} \)
- \( \gamma = \text{vector of regression coefficients on the gene-gene specific effects. It quantifies the effect of the pathway components on the longitudinal SBP outcome.} \)
- \( \eta = \text{regression coefficients that capture the variation of gene by gene interactions with age (as a discrete variable) and sex on } SBP. \text{It quantifies the age-specific effect of the pathway on the longitudinal SBP outcome.} \)
- \( u_i \sim N(0, \sigma^2_{u}) = \text{random intercept for each individual } i \)
- \( \epsilon_{it} \sim N(0, \sigma^2_{\epsilon}) = \text{Within individual error term with variance } \sigma^2_{\epsilon} \)
- The \( u'_i s \) are assumed correlated and independent from the \( \epsilon_{i}'s \).
Results
Comparing extreme gene-network profiles
Figure legends

- Only presenting Bonferroni-corrected $p$-values $< 0.0001$
- Effects are presented separately by sex
  - Females
  - Males
- Increases to SBP are denoted by dashed lines
- Reductions to SBP are denoted by solid lines
- Thickness of the line indicates the level of significance (i.e. thicker line = more statistically significant than thinner lines)
- Colour of the line indicates the effect size (i.e. the darker the line, the larger the effect compared to lighter coloured lines = smaller the effect size)
Extreme top 5% (< 15 years)
Extreme top 5% (15+ years)
CONCLUSIONS

- Children aged over 15 years had a much more active gene-network influencing SBP compared to children aged < 15 years.

- For children aged less than 15 years only males were statistically significantly associated with elevated SBP:
  - IGF1-IGFBP4
  - IGF1R-IGFBP1-IGFBP3

- For females aged 15 years and over, increases to extreme SBP was observed between:
  - IGF2 and IGFBP2 and IGFBP4
  - IGFBP2-IGFBP5 (and IGF1R-IGFBP5)

- For males aged 15 years and over, increases to extreme SBP was observed between:
  - IGF2 and IGFBP2 and IGFBP5
  - IGF1R-IGFBP4
Overlapping effects between males and females for increasing elevated SBP was observed for the gene-gene interactions of IGF2-IGFBP2-IGFBP5.
MEANING AND RELEVANCE

- The results attained are reasonable and align logically with current literature.
- Polymorphisms within IGF2 have already been shown to influence regulation of blood pressure in obese children.
- We found that this gene-network is modified with age; this in itself may be due to a number of reasons including diet, hormones and developmental growth over time, particularly post-puberty.
FUTURE

- Further investigation using this method and larger datasets would be ideal to validate our findings and improve accuracy surrounding the estimates produced from these models and further improve the power to detect complex interactions.

- Through characterizing the association between multiple genes and disease outcomes we will offer new insight into disease aetiology whilst providing tools for making individualized treatment decisions.
ACKNOWLEDGEMENTS

Statistics in Medicine

Special Issue Paper

Received 1 November 2010, Accepted 26 July 2011 Published online 14 October 2011 in Wiley Online Library

(wileyonlinelibrary.com) DOI: 10.1002/sim.4370

A two-stage mixed-effects model approach for gene-set analyses in candidate gene studies

Roula Tsonaka, a,† Annette H. M. van der Helm-van Milb and Jeanine J. Houwing-Duistermaat a

Lunenfeld-Tanenbaum Research Institute
Mount Sinai Hospital
Joseph and Wolf Lebovic Health Complex

THE UNIVERSITY OF WESTERN AUSTRALIA

THE UNIVERSITY OF ADELAIDE

THE JOANNA BRIGGS INSTITUTE